Efficacy and safety at 24 weeks of daily clinical use of tofacitinib in patients with rheumatoid arthritis

We evaluated the efficacy and safety of tofacitinib in patients with rheumatoid arthritis (RA) in a real-world setting. Seventy consecutive patients, for whom tofacitinib was initiated between November 2013 and May 2016, were enrolled. All patients fulfilled the 2010 ACR/EULAR classification criteri...

Full description

Saved in:
Bibliographic Details
Published in:PloS one 2017-05, Vol.12 (5), p.e0177057-e0177057
Main Authors: Iwamoto, Naoki, Tsuji, Sosuke, Takatani, Ayuko, Shimizu, Toshimasa, Fukui, Shoichi, Umeda, Masataka, Nishino, Ayako, Horai, Yoshiro, Koga, Tomohiro, Kawashiri, Shin-Ya, Aramaki, Toshiyuki, Ichinose, Kunihiro, Hirai, Yasuko, Tamai, Mami, Nakamura, Hideki, Terada, Kaoru, Origuchi, Tomoki, Eguchi, Katsumi, Ueki, Yukitaka, Kawakami, Atsushi
Format: Article
Language:English
Subjects:
Active control
Age
Aged
Antibodies
Anticancer properties
Antirheumatic Agents - adverse effects
Antirheumatic Agents - therapeutic use
Arthritis, Rheumatoid - drug therapy
Bayesian analysis
Biology and Life Sciences
Bone grafts
CD4 antigen
CD8 antigen
Citrulline
Classification
Clinical medicine
Clinical trials
Complications
Cytokine receptors
Cytokines
Demographics
Disease prevention
Dosage and administration
Drug therapy
Effectiveness
Female
Health risk assessment
Herpes zoster
Humans
Immunology
Inhibition
Interferon
Interleukin 12
Interleukin 17
Interleukin 2
Interleukin 6
Interleukin 7
Joint diseases
Male
Medicine and Health Sciences
Middle Aged
Monoclonal antibodies
Necrosis
Physical Sciences
Piperidines - adverse effects
Piperidines - therapeutic use
Pyrimidines - adverse effects
Pyrimidines - therapeutic use
Pyrroles - adverse effects
Pyrroles - therapeutic use
Rheumatoid arthritis
Rheumatoid factor
Rheumatology
Safety
Safety and security measures
Side effects
Statistical analysis
Therapy
TNF inhibitors
Tofacitinib
Transplantation
Tumor necrosis factor-TNF
Tumors
University graduates
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We evaluated the efficacy and safety of tofacitinib in patients with rheumatoid arthritis (RA) in a real-world setting. Seventy consecutive patients, for whom tofacitinib was initiated between November 2013 and May 2016, were enrolled. All patients fulfilled the 2010 ACR/EULAR classification criteria for RA. All patients received 5 mg of tofacitinib twice daily and were followed for 24 weeks. Clinical disease activity indicated by disease activity score (DAS)28-ESR, the simplified disease activity index, and the clinical disease activity index as well as adverse events (AEs) were evaluated. Statistical analysis was performed to determine which baseline variables influenced the efficacy of tofacitinib at 24 weeks. Fifty-eight patients (82.9%) continued tofacitinib at 24 weeks. Clinical disease activity rapidly and significantly decreased, and this efficacy continued throughout the 24 weeks: i.e., DAS28-ESR decreased from 5.04 ± 1.33 at baseline to 3.83 ± 1.11 at 4 weeks and 3.53 ± 1.17 at 24 weeks (P
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0177057